Category: Tysabri

While Copaxone and Interferon-Betas Continue to Dominate Treatment in MS, Tysabri Shows Modest Increase in First-Line Use

BURLINGTON, Mass., Nov 02, 2011 (BUSINESS WIRE) — Decision Resources, one of the world’s leading research and advisory firms focusing…

Stuart Schlossman

MS Activity Returns Soon After Stopping Natalizumab (Tysabri)

AMSTERDAM – Significant percentages of patients with relapsing-remitting multiple sclerosis who discontinue natalizumab but start another medication experience a return of…

Stuart Schlossman

Stopping natalizumab (Tysabri) to take a medication vacation, may mean renewed disease activity within six months

ECTRIMS: Fast MS Comeback May Ruin Drug ‘Holiday’ This report is part of a 12-month Clinical Context series. By John Gever,…

Stuart Schlossman

Natalizumab (Tysabri)-Associated PML Survival Rates Exceed 80%

AMSTERDAM—Early diagnosis through enhanced clinical vigilance and optimal management of progressive multifocal leukoencephalopathy (PML) may improve outcomes, according to data…

Stuart Schlossman

Natalizumab (Tysabri) Effective for Relapsing-Remitting MS

Natalizumab is well tolerated and reduces relapses and disability at two years in patients with relapsing-remitting multiple sclerosis, according to…

Stuart Schlossman

Two out of Three Patients Report Discontinuing Tysabri Without Doctors’ Advice

PatientsLikeMe Releases First in Series of Reports on Real-World Patient Experiences With Top Multiple Sclerosis Drugs CAMBRIDGE, MA–(Marketwire – Sep…

Stuart Schlossman

Clinical Reviews of JCV and PML in Digital.pdf format

A Digital View. Information provided by: Cherie C. Binns RN BS MSCN Understanding the complexities Click here: http://viewer.zmags.com/publication/f84595ef#/f84595ef/2  to review this Biogen Digital…

Stuart Schlossman

Inhibikase Therapeutics Receives FDA Clearance for Phase II Trial of IkT-001 to Treat JC Virus Infection, the Cause of Progressive Multifocal Leukoencephalopathy (PML) in Multiple Sclerosis Patients

– Host-Targeted Antiviral Blocks JC Virus Entry – PR Newswire ATLANTA, Aug. 16, 2011 /PRNewswire/ — Inhibikase Therapeutics, Inc., an emerging leader in…

Stuart Schlossman

Understanding the Complexities of JCV and PML

Now Available Online at www.neurologyreviews.com  Clinical Reviews of JCV and PML:  Understanding the Complexities of JCV and PML This new…

Stuart Schlossman

Unilabs to Develop Companion Dx for Biogen Idec Drug

July 6, 2011 By a GenomeWeb staff reporter NEW YORK (GenomeWeb News) – Unilabs will develop a companion diagnostic assay for…

Stuart Schlossman

Categories

Latest Blog Posts